Expert Interview
A Second Look: Discussing the SELECT trial and WEGOVY's (semaglutide) potential to reduce the risk of major adverse cardiovascular events (MACE) with an endocrinologist
Ticker(s): NVO, LLYInstitution: University of Pittsburgh
- Director of Endocrinology and Metabolism Clinical Research Core and Translational Research Center at UPMC.
- Treats 800- 900 obese patients per year who are at risk for major adverse cardiac events.
- Clinical interests are in the areas of diabetes and general endocrinology; Research interests in the etiology and treatment of insulin resistance in humans, medications that improve insulin resistance and beta cell function, and is currently investigating the pathogenesis of pancreatitis-related diabetes to identify new possibilities of prevention and treatment.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
